期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血管紧张素转化酶抑制剂在慢性心力衰竭中的应用 被引量：7

Angiotensin-converting enzyme inhibitors in the treatment of chronic heart failure
原文传递
导出
摘要 慢性心力衰竭(CHF)的治疗目标不仅仅是改善症状、提高生活质量,更重要的是延缓和防止心室重构发展,降低CHF死亡率和住院率,目前临床药物治疗仍居主导地位。血管紧张素转化酶抑制剂(ACEI)一直是CHF治疗的一线药物,血管紧张素Ⅱ受体阻断剂(ARB)对CHF预后也有益,但与ACEI相比,其并无显著优势。本文综述ACEI在CHF治疗中的临床地位。 The target of chronic heart failure（CHF）treatment is not only to improve the symptoms and life quality,but also to delay or prevent from the myocardial reconstruction development in order to decrease the mortality and hospitalization rate.Drug therapy is still the major strategy for CHF.Angiotensin-converting enzyme inhibitors（ACEIs） are always the first-line drugs in the treatment of CHF.Recently,angiotensin Ⅱ receptor blockers（ARBs） have been demonstrated to improve the prognosis of CHF,but there is no much superiority compared with ACEIs.This review discusses the clinical application of ACEIs for CHF.
作者 李新立 周芳
机构地区 南京医科大学第一附属医院心内科
出处 《世界临床药物》 CAS 2011年第11期659-662,共4页 World Clinical Drug
关键词 慢性心力衰竭(CHF) 血管紧张素转化酶抑制剂(ACEI) 血管紧张素Ⅱ受体阻断剂(ARB) chronic heart failure（CHF） angiotensin-converting enzyme inhibitor（ACEI） angiotensin Ⅱ receptor blocker（ARB）
分类号 R972.4 [医药卫生—药品] R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献18

  • 1中华医学会心血管病学分会 中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南.中华一t5血管病杂志,2007,.
  • 2The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) [J]. N Engl J Med, 1987, 316(23): 1429-1435.
  • 3The SOLVD investigators. Effect of enalapril on mortality and the development heart failure in asymptomatic patients with reduced left ventricular ejection fractions [J]. N Engl J Med, 1992, 327 (10) : 685-691.
  • 4Lamas GA, Flaker GC, Mitchell G, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction[J]. Circulation, 1995, 92 (5):1101-1109.
  • 5The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure[J]. Lancet, 1993, 342 (8875): 821-828.
  • 6Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: VaI-HeFT echocardiographic study [J]. J Am Coll Cardiol, 2002, 40 (5) : 970-975.
  • 7Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure [J]. J Am Med Assoc, 1995, 273 (18) : 1450-1456.
  • 8Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with leftventricular systolic dysfunction: a follow-study[J]. Lancet, 2003, 361 (9372): 1843-1848.
  • 9Cleland JG, Tendera M, Adamus J, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study [J]. Eur J Heart Fail, 1999, 1 (3) : 211-217.
  • 10Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II [J]. Lancet, 2000, 355 (9215) : 1582-1587.

二级参考文献65

  • 1<血管紧张素转换酶抑制剂在肾脏病中正确应用>专家协会组.血管紧张素转换酶抑制剂在肾脏病中正确应用的专家共识[J].中华肾脏病杂志,2006,22(1):57-58. 被引量：69
  • 2Lopez-Sendon J,Swedberg K,McMurray J,et al.Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease.The Task Force on ACE-inhibitors of the European Society of Cardiology.Eur Heart J,2004,25(16):1454-1470.
  • 3The Heart Outcomes Prevention Evaluation Study Investigators.Effects of an angiotensin-converting-enzyme inhibitor,ramipril,on cardiovascular events in high-risk patients.N Engl J Med,2000,342 (3):145-153.
  • 4The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA,2002,288 (23):2981-2997.
  • 5Liu L,for the Chinese Cardiac Study (CCS-1) Collaborative Group.Long-term mortality in patients with myocardial infarction:impact of early treatment with captopril for 4 weeks.Chin Med J,2001,114(2):115-118.
  • 6Jong P,Yusuf S,Rousseau MF,et al.Effect of enalapril on 12-year of survival and life expectancy in patients with left ventricular systolic dysfunction:a follow-up study.Lancet,2003,361(9372):1843-1848.
  • 7Bosch J,Lonn E,Pogue J,et al.Long-term effects of ramipril on cardiovascular events and on diabetes:results of the HOPE study extension.Circulation,2005,112(9):1339-1346.
  • 8Cooper WO,Hernandez-Diaz S,Arbogast PG,et al.Major congenital malformations after first-trimester exposure to ACE inhibitors.N Engl J Med,2006,354(23):2443-2451.
  • 9Swedberg K,Leland J,Dargie H,et al.Guidelines for the diagnosis and treatment of chronic heart failure:executive summary (update 2005).The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.Eur Heart J,2005,26(11):1115-1140.
  • 10Hunt SA,Abraham WT,Chin MH,et al.ACC/AHA guideline update for the diagnosis and management of chronic heart failure in the adult-summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).Circulation,2005,112(11):1825-1852.

共引文献132

同被引文献63

引证文献7

二级引证文献69

世界临床药物
2011年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部